Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Given Average Rating of “Reduce” by Analysts

Shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) have received a consensus recommendation of “Reduce” from the nine ratings firms that are covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $28.00.

FMS has been the subject of several research reports. Jefferies Financial Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “moderate sell” rating to a “strong sell” rating in a research report on Tuesday, February 24th. Erste Group Bank lowered Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th. The Goldman Sachs Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a report on Tuesday, January 20th. Wall Street Zen upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 20th. Finally, Morgan Stanley reissued an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, January 27th.

Fresenius Medical Care AG & Co. KGaA Trading Down 0.4%

Shares of FMS stock opened at $22.96 on Friday. The stock’s fifty day simple moving average is $23.22 and its 200 day simple moving average is $24.39. The company has a quick ratio of 0.92, a current ratio of 1.26 and a debt-to-equity ratio of 0.40. Fresenius Medical Care AG & Co. KGaA has a twelve month low of $20.94 and a twelve month high of $30.46. The firm has a market capitalization of $13.31 billion, a P/E ratio of 12.02, a P/E/G ratio of 0.67 and a beta of 0.91.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its quarterly earnings results on Tuesday, February 24th. The company reported $0.83 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.16. The company had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $4.80 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 8.73% and a net margin of 5.03%. As a group, sell-side analysts predict that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

Institutional investors have recently bought and sold shares of the business. Pzena Investment Management LLC lifted its stake in Fresenius Medical Care AG & Co. KGaA by 1.0% in the 3rd quarter. Pzena Investment Management LLC now owns 14,816,852 shares of the company’s stock valued at $390,128,000 after purchasing an additional 153,870 shares during the last quarter. Morgan Stanley raised its stake in Fresenius Medical Care AG & Co. KGaA by 47.2% in the 4th quarter. Morgan Stanley now owns 2,939,839 shares of the company’s stock worth $70,027,000 after purchasing an additional 942,497 shares in the last quarter. Todd Asset Management LLC raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 5.2% in the third quarter. Todd Asset Management LLC now owns 1,303,424 shares of the company’s stock valued at $34,319,000 after buying an additional 64,311 shares in the last quarter. Teachers Retirement System of The State of Kentucky increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 8.3% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 816,200 shares of the company’s stock worth $21,491,000 after purchasing an additional 62,700 shares during the period. Finally, Integral Health Asset Management LLC grew its stake in Fresenius Medical Care AG & Co. KGaA by 44.4% during the fourth quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock worth $15,483,000 after buying an additional 200,000 shares in the last quarter. Institutional investors and hedge funds own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.